10 Things You Didn't Know About Using GLP-1s In Perimenopause

Key Points:

• GLP-1 receptor agonists, such as semaglutide, are being microdosed in perimenopausal women to address declining GLP-1 signaling caused by estrogen loss, which can lead to increased hunger, fat accumulation, and blood sugar issues.
• Microdosing involves using significantly lower doses than standard therapy, aiming to improve metabolic health and insulin sensitivity before weight loss occurs, with fewer gastrointestinal side effects.
• Combining GLP-1 therapy with hormone therapy may enhance weight loss and metabolic benefits, as estrogen boosts GLP-1 receptor signaling and supports muscle preservation.
• Muscle loss is a significant risk with GLP-1 use, especially in perimenopausal women, making strategies like microdosing, adequate protein intake, and resistance training important to mitigate this issue.
• While promising, microdosing GLP-1s lacks rigorous scientific validation and is considered off-label; individualized care with knowledgeable providers is recommended until more research is available.